FLT3 and acute myeloid leukemia: Modest anti-leukemic activity seen with PARPi monotherapy in cell lines. Reduction in AML-initiating FLT3-ITD+ cells and clonogenic cells in bone marrow under hypoxic conditions.No significant reduction in leukemic burden or prolongation of survival in primary FLT3-ITD+ AML murine xenografts.